As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies.
Please note that following information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late August 2022.
These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.